ENTAEnanta Pharmaceuticals, Inc.
What is the market doing?
No clear lean: nothing decisive, though in a downtrend (−12% vs 200-day).
In a downtrend, below its 50- and 200-day averages. Price is −12% vs its 200-day average.
Heavily shorted, settled Sep 30, 2026, more than a week of normal trading to cover, a crowded exit.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How ENTA is trading
Enanta Pharmaceuticals, Inc. is +11% over the past year while the S&P 500 is +16%: 5.1 points behind the market.
1-year return · S&P 500 +16%
- vs 200-day average
- −12%
vs 200-day average · a clear downtrend
- RSI (14)
- 39
RSI (14) · neutral
- Below its 52-week high
- 31%
Below its 52-week high
Details›
- Last close2026-10-23
- $11.64
- 1 monthS&P 500 −0.94%
- −2.9%
- 1 yearS&P 500 +16%
- +11%
- 5 yearsS&P 500 +86%
- −84%
- vs 50-day average$12.70
- −8.4%
- 52-week high
- $16.85
- 52-week low
- $10.47
- Annualised volatility
- 91%
| Year | Return |
|---|---|
| 2026 (year to date) | −26% |
| 2025 | +174% |
| 2024 | −39% |
| 2023 | −80% |
| 2022 | −38% |
| 2021 | +78% |
| 2020 | −32% |
| 2019 | −13% |
| 2018 | +21% |
| 2017 | +75% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 5 of 10 | +4.7% |
| Feb | 10 | 6 of 10 | +10% |
| Mar | 10 | 5 of 10 | −3.1% |
| Apr | 10 | 5 of 10 | −2.0% |
| May | 10 | 3 of 10 | −7.6% |
| Jun | 10 | 6 of 10 | +6.9% |
| Jul | 11 | 5 of 11 | −2.4% |
| Aug | 11 | 6 of 11 | +3.6% |
| Sep | 11 | 3 of 11 | −1.9% |
| Oct | 11 | 4 of 11 | −1.0% |
| Nov | 10 | 6 of 10 | +4.4% |
| Dec | 10 | 6 of 10 | −1.6% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.